RemeGen Co., Ltd. (688331)

Overview

RemeGen Co., Ltd. is a prominent biopharmaceutical company engaged in the discovery, development, and commercialization of innovative biologics. Focused on addressing the unmet medical needs in autoimmune diseases, oncology, and ophthalmic diseases, the company has established a significant footprint in Mainland China and the United States. Founded in 2008 and headquartered in Yantai, the People's Republic of China, RemeGen is at the forefront of providing advanced treatments for diseases with critical demands for more effective therapeutic options.

Products and Services

Telitacicept (RC18): Designed for the treatment of systemic lupus erythematosus, an autoimmune disease. RC18 is currently under phase III clinical trials for the treatment of other autoimmune conditions such as neuromyelitis optica spectrum disorder and rheumatoid arthritis. Additionally, it is undergoing phase II clinical trials for addressing IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis.

Disitamab Vedotin (RC48): This product is targeted for the treatment of various cancers, leveraging its ability to target and destroy cancer cells while sparing healthy cells, thereby minimizing side effects compared to conventional treatments.

RC28: Has completed Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, showcasing its potential in addressing significant ophthalmic conditions.

RC98: A PD-L1 monoclonal antibody currently under Phase I clinical trial, developed for the treatment of solid tumors. Its mechanism aims at enhancing the immune system's ability to recognize and eliminate cancer cells.

RC88: This candidate is in Phase 1 clinical trials for the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors. RC88 represents RemeGen's foray into targeting a range of challenging solid tumors with innovative biologic treatment options.

RC108: Another promising candidate in Phase 1 clinical trials aimed at treating various solid tumors, demonstrating the company's commitment to expanding its oncology pipeline with novel therapeutic agents.

Pre-clinical Development Products (RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198): These are under pre-clinical development to treat various solid tumors, highlighting RemeGen's endeavors in broadening its therapeutic options in oncology.

RC218 and RC228: Aimed at treating ophthalmopathy, these products are also under pre-clinical development, signifying the company's efforts in combating ophthalmic diseases with groundbreaking biologics.